theMednetRegister

Radiation Oncology

ESMO 2025   

Questions discussed in this category



Papers discussed in this category

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 18
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.
The New England journal of medicine, 2025 Oct 19
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
Future oncology (London, England), 2023 Aug 01
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
J. Clin. Oncol., 2020 Sep 20
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
The New England journal of medicine, 2024 Mar 21
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
The New England journal of medicine, 2025 May 31
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
The New England journal of medicine, 2025 Oct 29
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
The New England journal of medicine, 2025 Oct 20
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
The New England journal of medicine, 2025 Oct 19
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.
Lancet Oncol, 2021 Mar 12
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 19
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.
The New England journal of medicine, 2025 Oct 19
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Future oncology (London, England), 2025 Nov 13
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line V600E-mutant metastatic colorectal cancer.
Lancet (London, England), 2025 Oct 20
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.
The New England journal of medicine, 2025 Jun 01
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
Future oncology (London, England), 2024 Jul 23
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.
Nature medicine, 2025 Oct 18
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial.
J Clin Oncol, 2019 Jun 02
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
The New England journal of medicine, 2025 Oct 19
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, -Mutated Advanced NSCLC.
Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 17
\zaAlectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the Phase III ALEX study.
The Lancet. Oncology, 2025 Sep 08
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.

Related Topics in Radiation Oncology

Copyright © 2026 theMednet
All Rights Reserved.